Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Orally administered hydrocortisone and the intraocular pressure
Oral application of short acting corticosteroids is vey often indicated in canine medicine. How high is the risk for a nonglaucomatous dog to develop an iatrogenic glaucoma under oral steroid therapy? A very important question. One result of this recently published study: hydrocortisone seems to be no problem for the eye pressure.

This study was undertaken to determine the effect of oral hydrocortisone on intraocular pressure (IOP) in ocular normotensive dogs. Seventeen ocular normotensive dogs were included.

Dogs were randomly assigned to treatment (n = 9) and control (n = 8) groups.
Dogs in the treatment group received hydrocortisone, 3.3 mg/kg PO every 8 h, and dogs in the control group received gelatin capsule placebo PO every 8 h for 5 weeks.
Applanation tonometry was performed on both eyes of all dogs prior to treatment and then once weekly for 5 weeks during hydrocortisone treatment.

Results: No significant effect of treatment was noted for right (P = 0.1013) or left (P = 0.1157) eyes during the treatment period, nor was there significant interaction of treatment by week for the right (P = 0.9456) or left (P = 0.3577) eyes. A significant rise in IOP over the treatment period was noted in both right (P < 0.0001) and left (P = 0.0006) eyes of both groups, but was unrelated to treatment.

Thus, orally administered hydrocortisone does not significantly increase IOP in nonglaucomatous dogs when administered over a 5-week period.



Source: Herring, Ian P., Herring, Erin S. & Ward, Daniel L. (2004): Effect of orally administered hydrocortisone on intraocular pressure in nonglaucomatous dogs. In: Veterinary Ophthalmology 7 (6), 381-384.




Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Patient-specific facemask to facilitate brain biopsymembers
The objective of this pilot study was to describe the application and first preliminary data of a novel MRI and CT compatible patient-specific facemask for stereotactic brain biopsy of intracranial lesions in dogs. Five client-owned dogs presenting for neurological deficits consistent with forebrain disease were included in the study. All dogs had MRI findings consistent with an intracranial lesion. But biopsies in this region are not easy to obtain. Does an individual face mask help?

  • RET-He to diagnose iron-deficient erythropoiesis in dogsmembers
  • Hypertriglyceridemia-Associated Proteinuria in Miniature Schnauzersmembers
  • Gastrointestinal dysmotility disorders in critically ill animalsmembers
  • Disorder of sex development in a cat with chromosome mosaicism members
  • Generalized discoid lupus erythematosus in dogs members
  • Epidermolysis bullosa acquisita in dogsmembers
  • Chiari-Like Malformation and Syringomyelia in American Brussels Griffon Dogsmembers
  • Efficacy and Potential Complications of Transjugular Liver Biopsymembers
  • Hypomagnesemia in Brachycephalic Dogsmembers
  • Comparison of two minimally invasive techniques for liver biopsy members
  • Topical aqueous sirolimus and the tear production members
  • JAK 1/2 inhibitor in the treatment of canine B-cell lymphomamembers


  • [ Home ] [ About ] [ Contact / Request ][ Disclaimer ]

    Copyright © 2001-2016 VetContact GmbH
    All rights reserved